ESMO 2020

2020-09-19 - 2020-09-21
Online, Virtual

ASCO 2020

2020-05-29 - 2020-05-31
Online, Virtual

ESMO 2019

2019-09-27 - 2019-10-01
Barcelona, Spain

ASCO 2019

2019-05-31 - 2019-06-04
Chicago, United States

EADO 2019

2019-04-24 - 2019-04-27
Paris, France

BCC 2019

2019-03-20 - 2018-03-23
Vienna, Austria

SABCS 2018

2018-12-04 - 2018-12-08
San Antonio, United States

ESMO 2018

2018-10-19 - 2018-10-23
Munich, Germany

ASCO 2018

2018-06-01 - 2018-06-05
Chicago, United States
Search in Scientific Content:
Date
Filters:
First-line
13:30

First-line nivolumab + ipilimumab combined with 2 cycles of platinum-based chemotherapy vs 4 cycles of chemo in advanced non-small cell lung cancer: Patient-reported outcomes from CheckMate 9LA

Presenter: David P. Carbone
ESMO 2020
Current st
10:47

Current state of frontline immunotherapy options in the treatment of mNSCLC and the effect of COVID-19 pandemic on lung cancer management

Presenter: Luis Paz-Ares
ESMO 2020
Clinical c
12:58

Clinical considerations of melanoma treatment in 2020

Presenter: Paolo A. Ascierto
ESMO 2020
Evolving t
7:33

Evolving treatment paradigms for Head and Neck Squamous Cell Carcinoma

Presenter: Ezra E. W. Cohen
ESMO 2020
Nivolumab
18:11

Nivolumab plus chemotherapy versus chemo as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: First results of the checkmate 649 study

Presenter: Markus Moehler
ESMO 2020
MONARCH-E
9:22

MONARCH-E trial: Abemaciclib reduces recurrence in HR+ high risk early breast cancer

Presenter: Stephen Johnston
ESMO 2020
Triple neg
20:34

Triple negative breast cancer highlights in ESMO 2020

Presenter: Hope S. Rugo
ESMO 2020
Overall su
7:35

Overall survival results from SOLAR-1, a phase III study of alpelisib + fulvestrant for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer

Presenter: Hope S. Rugo
ESMO 2020
The Impact
7:10

The Impact of COVID-19 on Oncology Professionals: Initial Results of The ESMO Resilience Task Force Survey Collaboration

Presenter: Susana Banerjee
ESMO 2020
Estimation
12:21

Estimation of European cancer burden for the year 2020

Presenter: Manola Bettio
ESMO 2020
Adjuvant n
11:36

Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238

Presenter: Jeffrey Weber
ESMO 2020
An interna
6:02

An international randomized trial, comparing post-operative conformal radiotherapy to no PORT, in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement. Primary end-point analysis of Lung ART NCT00410683

Presenter: Cécile Le Pechoux
ESMO 2020
KEYNOTE-02...
7:07

KEYNOTE-024 5-year OS update: first-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumor proportion score (TPS) ≥50%

Presenter: Julie R. Brahmer
ESMO 2020
Pembrolizu
5:19

Pembrolizumab Plus Chemotherapy Versus Chemotherapy as First-Line Therapy in Patients With Advanced Esophageal Cancer: The Phase 3 KEYNOTE-590 Study

Presenter: Ken Kato
ESMO 2020
COVID-19 a
11:47

COVID-19 and cancer management

Presenter: Guy Jerusalem
ESMO 2020
Nivolumab
9:31

Nivolumab Plus Cabozantinib Improves OS and PFS in CheckMate-9ER Frontline RCC Trial

Presenter: Camillo Porta
ESMO 2020
Effects of
11:15

Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women

Presenter: Richard Gray
Specialty: Breast Cancer
Alpelisib
14:48

Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the Phase III SOLAR-1 trial

Presenter: Dejan Juric
Specialty: Breast Cancer
Lifestyle
8:40

Lifestyle Intervention Helped Breast Cancer Survivors Lose Weight, and Was Associated with Higher Disease-free Survival Rates

Presenter: Wolfgang Janni
Specialty: Breast Cancer
Choice of
8:39

Choice of Surgery May Affect Quality of Life for Young Breast Cancer Survivors

Presenter: Laura Dominici
Specialty: Breast Cancer
Circulatin
10:32

Circulating Tumor Cell Count Could Help Choose Treatment for Metastatic Breast Cancer Patients

Presenter: Francois-Clement Bidard
Specialty: Breast Cancer
Axillary R
9:45

Axillary Radiotherapy and Lymph Node Surgery Yielded Comparable 10-year Outcomes for Patients with Breast Cancer

Presenter: Emiel J. T. Rutgers
Specialty: Breast Cancer
Accelerate
6:19

Accelerated Partial Breast Irradiation, Although Close, was Not Equivalent to Whole Breast Irradiation To Control Ipsilateral Breast Tumor Recurrence

Presenter: Fank Vicini
Specialty: Breast Cancer
A randomiz
10:32

A randomized placebo controlled phase III trial of low dose tamoxifen for the prevention of recurrence in women with operated hormone sensitive breast ductal or lobular carcinoma in situ

Presenter: Andrea De Censi
Specialty: Breast Cancer
PALLET: A
12:51

PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib

Presenter: Mitchell Dowsett
Specialty: Breast Cancer
Phase III
9:33

Phase III KATHERINE Clinical Trial Crossed Early Reporting Boundary and Met its Primary Endpoint

Presenter: Charles E. Geyer, Jr
Specialty: Breast Cancer
Adjuvant C
8:05

Adjuvant Capecitabine Did Not Significantly Improve Outcomes for Patients With Early-stage Triple-negative Breast Cancer

Presenter: Miguel Martín
Specialty: Breast Cancer
Adjuvant C
7:33

Adjuvant Chemotherapy Might Not Add Benefit in Breast Cancer Patients who Have Excellent Response to Neoadjuvant Chemotherapy

Presenter: Laura Spring
Specialty: Breast Cancer
Delaying A
5:48

Delaying Adjuvant Chemotherapy Associated With Worse Outcomes for Patients With Triple-negative Breast Cancer

Presenter: Zaida Morante
Specialty: Breast Cancer
Low-Dose T
9:12

Low-Dose Tamoxifen Was Safe and Effective at Reducing Recurrence and New Breast Disease for Patients With DCIS, LCIS, and ADH

Presenter: Andrea De Censi
Specialty: Breast Cancer
Increasing
11:01

Increasing the dose intensity of adjuvant chemotherapy: an EBCTCG meta-analysis

Presenter: Richard Gray
Specialty: Breast Cancer
Phase Ib/I
8:36

Phase Ib/II Study Evaluating Safety and Efficacy of Pembrolizumab and Trastuzumab in Patients with Trastuzumab-Resistant HER2-positive Advanced Breast Cancer: Results from the PANACEA Study (IBCSG 45-13/BIG 4-13/KEYNOTE-014)

Presenter: Sherene Loi
Specialty: Breast Cancer